Skip to main content

Advertisement

Table 2 Effect of memantine on discontinuation, efficacy and safety outcomes in patients with Alzheimer’s disease

From: Predictors of discontinuation, efficacy, and safety of memantine treatment for Alzheimer’s disease: meta-analysis and meta-regression of 18 randomized clinical trials involving 5004 patients

  Na OR 95%CI I2 (%)
All-cause discontinuation 18 0.97 0.82, 1.14 14.9
Discontinuation due to AE 14 1.18 0.91, 1.53 34.4
Discontinuation due to LoE 7 0.40 0.18, 0.87 0
  N SMD 95%CI I2 (%)
Cognitive function 17 0.15 0.08, 0.22 24.3
Global change 10 0.16 0.08, 0.24 29.3
Neuropsychiatric symptoms 15 0.16 0.09, 0.24 27.2
Functional ability 10 0.07 −0.02, 0.15 14.7
  N OR 95%CI I2 (%)
Proportion patients AE 6 1.05 0.88, 1.25 0
Proportion patients SAE 10 0.89 0.70, 1.13 18.3
Mortality 13 1.03 0.74, 1.44 0
  1. AE adverse event, ChEI cholinesterase inhibitor, CI confidence interval, I2 heterogeneity, LoE lack of efficacy, N number of memantine-placebo comparisons, OR odds ratio, SAE severe adverse event
  2. aOne study included had a factorial design